Ameriprise’s Provention Bio, Inc. Common Stock PRVB Stock Holding History

Ameriprise’s Portfolio PRVB Stock Details PRVB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-412,127	Closed	-$9.93M	–	4057
2023 Q1	$9.93M	Buy	+412,127	New	+$5.17M	﹤0.01%	1779
2021 Q2	–	Sell	-28,330	Closed	-$298K	–	3994
2021 Q1	$298K	Sell	28,330 -427	-1%	-$6.01K	﹤0.01%	3599
2020 Q4	$488K	Buy	28,757 +2,640	+10%	+$39.6K	﹤0.01%	3356
2020 Q3	$335K	Buy	26,117 +1,330	+5%	+$16.8K	﹤0.01%	3395
2020 Q2	$350K	Buy	+24,787	New	+$313K	﹤0.01%	3311

Other funds holding PRVB

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Ameriprise's PRVB Position: Q2 2023 in Review

Ameriprise sold out of Provention Bio, Inc. Common Stock (PRVB) in Q2 2023, closing a stake of 412,127 shares — an estimated $9.93M sold.

Ameriprise first reported a position in PRVB in Q2 2020 and held it in 5 quarters. The position peaked at $9.93M in Q1 2023. 1 fund tracked by Wall St. Rank holds PRVB as of Q2 2023.

Ameriprise reported no remaining Provention Bio, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Ameriprise sold 412,127 Provention Bio, Inc. Common Stock shares in Q2 2023, an estimated $9.93M.
Ameriprise first reported a position in Provention Bio, Inc. Common Stock in Q2 2020 and held it in 5 quarters.
Ameriprise's Provention Bio, Inc. Common Stock position peaked at $9.93M in Q1 2023.
1 fund tracked by Wall St. Rank held Provention Bio, Inc. Common Stock as of Q2 2023.

Based on Ameriprise's 13F filing for Q2 2023, filed 14 Aug 2023.